CN101970486A - 特异于血管内皮生长因子(vegf)的促血管发生同工型的抗体 - Google Patents

特异于血管内皮生长因子(vegf)的促血管发生同工型的抗体 Download PDF

Info

Publication number
CN101970486A
CN101970486A CN2008801226493A CN200880122649A CN101970486A CN 101970486 A CN101970486 A CN 101970486A CN 2008801226493 A CN2008801226493 A CN 2008801226493A CN 200880122649 A CN200880122649 A CN 200880122649A CN 101970486 A CN101970486 A CN 101970486A
Authority
CN
China
Prior art keywords
vegf
antibody
angiogenic
antibodies
epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801226493A
Other languages
English (en)
Chinese (zh)
Inventor
戴维·O·贝茨
史蒂文·J·哈珀
米丽亚姆·Y·曼戈卢斯
梅纳赫姆·泽维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Bristol
Philogene Inc
Original Assignee
University of Bristol
Philogene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Bristol, Philogene Inc filed Critical University of Bristol
Publication of CN101970486A publication Critical patent/CN101970486A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN2008801226493A 2007-10-25 2008-10-26 特异于血管内皮生长因子(vegf)的促血管发生同工型的抗体 Pending CN101970486A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98243807P 2007-10-25 2007-10-25
US60/982,438 2007-10-25
PCT/IL2008/001410 WO2009053987A1 (en) 2007-10-25 2008-10-26 Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (vegf)

Publications (1)

Publication Number Publication Date
CN101970486A true CN101970486A (zh) 2011-02-09

Family

ID=40385456

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801226493A Pending CN101970486A (zh) 2007-10-25 2008-10-26 特异于血管内皮生长因子(vegf)的促血管发生同工型的抗体

Country Status (7)

Country Link
US (1) US8592563B2 (https=)
EP (1) EP2203480A1 (https=)
JP (1) JP2011504092A (https=)
CN (1) CN101970486A (https=)
AU (1) AU2008315414A1 (https=)
CA (1) CA2703154A1 (https=)
WO (1) WO2009053987A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2066694T3 (en) * 2006-09-29 2016-02-08 Oncomed Pharm Inc Compositions and Methods for Diagnosing and Treating Cancer
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
HUE029661T2 (en) 2009-10-16 2017-03-28 Oncomed Pharm Inc A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
WO2011084791A2 (en) * 2009-12-21 2011-07-14 Mayo Foundation For Medical Education And Research Early marker of proteinuria in patients treated with an anti-vegf treatment
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US8623666B2 (en) * 2011-06-15 2014-01-07 Hoffmann-La Roche Inc. Method for detecting erythropoietin (EPO) receptor using anti-human EPO receptor antibodies
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
WO2014117053A1 (en) * 2013-01-27 2014-07-31 The Cleveland Clinic Foundation Anti-angiogenic vegf-ax isoform
ES2808153T3 (es) 2014-10-31 2021-02-25 Mereo Biopharma 5 Inc Terapia de combinación para tratamiento de enfermedad
WO2016194708A1 (ja) * 2015-05-29 2016-12-08 国立大学法人名古屋大学 尿中ＶＥＧＦ－Ａ１６５ｂを指標とした腎機能の検査方法及び検査装置、腎機能の検査装置として機能させるためのプログラム及び記録媒体
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6022541A (en) * 1991-10-18 2000-02-08 Beth Israel Deaconess Medical Center Immunological preparation for concurrent specific binding to spatially exposed regions of vascular permeability factor bound in-vivo to a tumor associated blood vessel
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
DE60235761D1 (de) * 2001-08-01 2010-05-06 Univ Bristol Clifton Isoform des vegfs
US20050009110A1 (en) 2003-07-08 2005-01-13 Xiao-Jia Chang Methods of producing antibodies for diagnostics and therapeutics
CA2604180A1 (en) * 2005-04-29 2006-11-09 (Osi) Eyetech, Inc. Vegf variants
US20080031815A1 (en) * 2006-07-27 2008-02-07 Xiaoyuan Chen Pet imaging of vascular endothelial growth factor receptor (VEGFR), compositions for VEGF cancer imaging, and methods of VEGF cancer imaging
GB0704678D0 (en) 2007-03-09 2007-04-18 Univ Bristol Pro- and anti-angiogenic treatments

Also Published As

Publication number Publication date
US20100272733A1 (en) 2010-10-28
CA2703154A1 (en) 2009-04-30
AU2008315414A1 (en) 2009-04-30
WO2009053987A1 (en) 2009-04-30
JP2011504092A (ja) 2011-02-03
US8592563B2 (en) 2013-11-26
EP2203480A1 (en) 2010-07-07

Similar Documents

Publication Publication Date Title
CN101970486A (zh) 特异于血管内皮生长因子(vegf)的促血管发生同工型的抗体
US20210220472A1 (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
KR102189409B1 (ko) 암배아성 항원-관련 세포 부착 분자 (ｃｅａｃａｍ)에 대한 항체
US6767541B2 (en) HER-2/neu overexpression abrogates growth inhibitory pathways
KR20180018762A (ko) Pd-l1 길항제 조합 치료
EA018717B1 (ru) Антитело или фрагмент антитела, которое связывается с белком ron человека, и его применение
MX2012009554A (es) Terapia anti-angiogenesis para el tratamiento del cancer ovarico.
MX2011004871A (es) Anticuerpos de receptor ii anti-tgf-beta.
US20230340122A1 (en) Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer
CN110882385A (zh) 抗pd-1抗体在治疗肿瘤中的用途
JP2019515670A (ja) がんをモニタリングし治療するための方法
JP2022519341A (ja) ヒトネクチン－２に特異的な抗体
WO2011143408A1 (en) Use of neuropilin-1 antagonists for the treatment of cancer
KR20200014277A (ko) 폐암을 예방 또는 치료하기 위한 amhrii-결합 화합물
CA2694644A1 (en) Pharmaceutical combinations
JP7075135B2 (ja) 増殖因子を標的とする二機能性分子を使用したがんの治療方法
EP3074037B1 (en) Methods for modulating angiogenesis of cancers refractory to anti-vegf treatment
WO2022223006A1 (zh) 抗pd-1抗体联合一线化疗治疗晚期非小细胞肺癌的用途
WO2011119656A1 (en) Anti-angiogenesis therapy for treating abdominal aortic aneurysm
CN120647760A (zh) 卷曲受体抗体及其用途
TW201716439A (zh) Ｈｅｒ３抗體
US11020478B2 (en) Methods for modulating angiogenesis of cancers refractory to anti-VEGF treatment
RU2797506C2 (ru) Соединения, связывающие AMHRII, для профилактики или лечения раковых заболеваний легкого
KR102207221B1 (ko) 도펠-타겟팅 분자를 이용한 병리학적 신생혈관 생성을 억제하는 방법
HK1213177A1 (zh) 抗-vegf抗体与化学治疗联合用於治疗乳腺癌的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110209